What a rheumatologist needs to know about yellow fever vaccine

被引:0
作者
Vanderley Oliveira, Ana Cristina [1 ]
Henrique da Mota, Licia Maria [1 ,2 ]
dos Santos-Neto, Leopoldo Luiz [2 ]
Tauil, Pedro Luiz [3 ]
机构
[1] Univ Brasilia FMUnB, Sch Med, Med Sci Program, Brasilia, DF, Brazil
[2] Hosp Forcas Armadas, Dept Internal Med, Brasilia, DF, Brazil
[3] Univ Brasilia FMUnB, Sch Med, Trop Med Program, Brasilia, DF, Brazil
关键词
Yellow fever; Yellow fever vaccine; Rheumatic diseases; Immunosuppressive agents; RHEUMATIC-DISEASES; BRAZIL; HEPATITIS; THERAPY; 17D; IMMUNOGENICITY; SURVEILLANCE; INFECTIONS; SAFETY; EVENT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with rheumatic diseases are more susceptible to infection, due to the underlying disease itself or to its treatment. The rheumatologist should prevent infections in those patients, vaccination being one preventive measure to be adopted. Yellow fever is one of such infectious diseases that can be avoided. The yellow fever vaccine is safe and effective for the general population, but, being an attenuated live virus vaccine, it should be avoided whenever possible in rheumatic patients on immunosuppressive drugs. Considering that yellow fever is endemic in a large area of Brazil, and that vaccination against that disease is indicated for those living in such area or travelling there, rheumatologists need to know that disease, as well as the indications for the yellow fever vaccine and contraindications to it. Our paper was aimed at highlighting the major aspects rheumatologists need to know about the yellow fever vaccine to decide about its indication or contraindication in specific situations. (C) 2013 Elsevier Editora Ltda. All rights reserved.
引用
收藏
页码:206 / 210
页数:5
相关论文
共 37 条
  • [1] American Academy of Pediatrics, 2009, RED BOOK, P72
  • [2] [Anonymous], 2010, DEP VIG EP
  • [3] Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett, Alan D. T.
    Teuwen, Dirk E.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2009, 21 (03) : 308 - 313
  • [4] Yellow fever vaccination in non-immunocompetent patients
    Bruyand, M.
    Receveur, M. -C.
    Pistone, T.
    Verdiere, C. -H.
    Thiebaut, R.
    Malvy, D.
    [J]. MEDECINE ET MALADIES INFECTIEUSES, 2008, 38 (10): : 524 - 532
  • [5] Hepatitis and death following vaccination with 17D-204 yellow fever vaccine
    Chan, RC
    Penney, DJ
    Little, D
    Carter, IW
    Roberts, JA
    Rawlinson, WD
    [J]. LANCET, 2001, 358 (9276) : 121 - 122
  • [6] Longitudinal myelitis associated with yellow fever vaccination
    Chaves, M.
    Riccio, P.
    Patrucco, L.
    Rojas, J. I.
    Cristiano, E.
    [J]. JOURNAL OF NEUROVIROLOGY, 2009, 15 (04) : 348 - 350
  • [7] Cooke A, 2008, CLIN EXP RHEUMATOL, V26, pS1
  • [8] Use of glucocorticoids and risk of infections
    Cutolo, Maurizio
    Seriolo, Bruno
    Pizzorni, Carmen
    Secchi, Maria Elena
    Soldano, Stefano
    Paolino, Sabrina
    Montagna, Paola
    Sulli, Alberto
    [J]. AUTOIMMUNITY REVIEWS, 2008, 8 (02) : 153 - 155
  • [9] TLR expression and NK cell activation after human yellow fever vaccination
    da Costa Neves, Patricia Cristina
    de Souza Matos, Denise Cristina
    Marcovistz, Rugimar
    Galler, Ricardo
    [J]. VACCINE, 2009, 27 (41) : 5543 - 5549
  • [10] Immunization in rheumatic diseases of. childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence
    Davies, K
    Woo, P
    [J]. RHEUMATOLOGY, 2002, 41 (08) : 937 - 941